Opinion|Videos|March 6, 2026
Toxicity Considerations With ADCs and Other Approaches in EGFR-Mutated NSCLC
Author(s)Joel Neal, MD, PhD, Sarah B. Goldberg, MD, MPH
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss toxicity considerations with ADCs and emerging therapies in EGFR-mutated NSCLC.
Advertisement
Episodes in this series
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, review safety considerations associated with antibody-drug conjugates such as datopotamab deruxtecan (Dato-DXd) and other emerging therapies in EGFR-mutated NSCLC. Neal discusses the management of key toxicities associated with Dato-DXd. Goldberg underscores the importance of early recognition and multidisciplinary management to minimize serious adverse outcomes while preserving clinical benefit.
Advertisement
Related to this article
Longer follow-up of the phase 3 INDIGO trial showed that vorasidenib lowered seizure rates in IDH-mutant glioma, an effect driven by oligodendroglioma.
Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.
Advertisement
Advertisement
Trending on OncLive
1
Dr Johnson on Immune Activation With Indoximod-Based Chemo-Immunotherapy in Recurrent Ependymoma
2
Tovorafenib Sustains Treatment-Free Intervals in R/R BRAF-Altered Pediatric Low-Grade Glioma
3
Dr Miller on Whole Genome Sequencing of CSF ctDNA in High-Grade Glioma
4
Patient Preferences Steer Decisions as Options Multiply Across EGFR-Mutated NSCLC
5